Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Exclusion Criteria

• •1. Prior chemotherapy or prior immunotherapy with any anti-CD20 monoclonal antibody
• •2. Prior radiotherapy in the last 6 weeks
• •3. Corticosteroids during the last 28 days, unless prednisone chronically administered at a dose \<20 mg/day for indications other than lymphoma or lymphoma-related symptoms
• •4. Major impairment of renal function (serum creatinine \> 2,5 x upper normal) or liver function (ASAT/ALAT \<2,5 x upper normal, total bilirubin \<2,5x upper normal), unless due to lymphoma involvement.
• •5. Impairment of bone marrow function (WBC \<3.0x109/L, ANC \<1.5x109/L, PLT \<100x109/L), unless due to lymphoma involvement
• •6. Evidence of clinically significant cardiac, neurological or metabolic disease, unless due to lymphoma involvement
• •7. Evidence of symptomatic central nervous system (CNS) disease
• •8. Active HBV and/or HCV infection
• •9. Known HIV infection
• •10. Prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer
• •11. Any psychiatric disease potentially hampering compliance with the study protocol and follow-up schedule
• •12. Potential to attend regular visits to the hospital, on an outpatient regimen
• •13. Hypersensibility to any compound of the study medication.
• •14. Non appropriate contraceptive method in women of childbearing potential or men
• •15. Treatment with any drug under research within 30 days previous to start the study medication.